Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 2, 2005, Pages 270-284

  Patel, Nick C ^a   Crismon, M Lynn ^a   Hoagwood, Kimberly ^b   Jensen, Peter S ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; BEHAVIOR DISORDER; CHILD PARENT RELATION; CHILD PSYCHIATRY; DIABETES MELLITUS; DRUG EFFICACY; DYSMENORRHEA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LANGUAGE; MEDLINE; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; OPPOSITIONAL DEFIANT DISORDER; PROBLEM SOLVING; PSYCHOTHERAPY; QUESTIONNAIRE; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CHILD; HUMANS; MODELS, PSYCHOLOGICAL;

EID: 19544392160     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.270     Document Type: Article

References (67)

1. Alpert JE, Spillmann MK: Psychotherapeutic approaches to aggressive and violent patients. Psychiatr Clin North Am 20:453-472, 1997.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, for the Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disrup-tive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. Aman MG, Singh NN, Stewart AW, Field CJ: Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89:492-502, 1985a.
4. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985b.
5. Aman MG, Tasse MJ, Rojahn J, Hammer D: The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57, 1996.
6. American Academy of Child and Adolescent Psychiatry: AACAP workforce fact sheet, [online] Available at http://www.aacap.org. Accessed on December 1, 2001.
7. American Academy of Child and Adolescent Psychiatry: Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry 41(Suppl 2):4S-25S, 2002.
8. Beail N: Psychoanalytic psychotherapy with men with intellectual disabilities: A preliminary outcome study. Br J Med Psychol 71:1-11, 1998.
9. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028, 2002.
10. Borduin CM, Mann BJ, Cone LT, Henggeler SW, Fucci BR, Blaske DM, Williams RA: Multisystemic treatment of serious juvenile offenders: Long-term prevention of criminality and violence. J Consult Clin Psychol 63:569-578, 1995.
11. Brestan EV, Eyberg SM: Effective psychosocial treatments of conduct-disordered children and adolescents: 29 years, 82 studies, and 5272 kids. J Clin Child Psychol 27:180-189, 1998.
12. Brosnan CA, Upchurch S, Schreiner B: Type 2 diabetes in children and adolescents: An emerging disease. J Pediatr Health Care 15:187-193, 2001.
13. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized, controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
14. Compton MT, Miller AH: Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 36:143-164, 2002.
15. Connor DF, Fletcher KE, Wood JS: Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967-974, 2001.
16. Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the pre-vention of relapse in patients with schizophrenia. N Engl J Med 346:16-22, 2002.
17. Dunbar F, Kusumakar V, Daneman D, Schulz M: Growth and sexual maturation in children are unaffected by long-term treatment with risperidone. Scottsdale (Arizona), Janssen Pharmaceutica, CNS Advisory Summit, February 23-26, 2003 (poster).
18. Feeney DJ, Klyklyo W: Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 35:1421-1422, 1996.
19. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B, for the Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
20. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
21. Findling RL, Schulz C, Reed MD, Blumer JL: The antipsychotics: A pediatric perspective. Pediatr Clin North Am 45:1205-1232, 1998.
22. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
23. Giedd JN: Bipolar disorder and attention-deficit/ hyperactivity disorder in children and adolescents. J Clin Psychiatry 61(Suppl 9):31-34, 2000.
24. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ: Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 35:187-191, 2001.
25. Goodwin R, Gould M, Blanco C, Olfson M: Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv 52:1081-1087, 2001.
26. Gracious BL, Findling RL: Antipsychotic medications for children and adolescents. Pediatr Ann 30:138-145, 2001.
27. Henggeler SW, Clingempeel WG, Brondino MJ, Pickrel SG: Four-year follow-up of multisystemic therapy with substance-abusing and substance-dependent juvenile offenders. J Am Acad Child Adolesc Psychiatry 41:868-874, 2002.
28. Hoagwood K, Olin SS: The NIMH blueprint for change report: Research priorities in child and adolescent mental health. J Am Acad Child Adolesc Psychiatry 41:760-767, 2002.
29. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB: Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557-565, 1999.
30. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliot G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal T: Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr 22: 60-73, 2001.
31. Kaplan SL, Simms RM, Busner J: Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 33:35-44, 1994.
32. Kazdin AE, Siegel TC, Bass D: Cognitive problem-solving skills training and parent management training in the treatment of antisocial behavior in children. J Consult Clin Psychol 60:733-747, 1992.
33. Kazdin AE: Treatments for aggressive and antisocial children. Child Adolesc Psychiatr Clin North Am 9:841-858, 2000.
34. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal symptoms. Arch Gen Psychiatry 40:1113-1117, 1983.
35. Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman RC: Increasing identification of psychosocial problems: 1979-1996. Pediatrics 105: 1313-1321, 2000.
36. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S: International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28, 2004.
37. Macaluso CJ, Bauer UE, Deeb LC, Malone JL, Chaudhari M, Silverstein J, Eidson M, Goldberg RB, Gaughan-Bailey B, Brooks RG, Rosenbloom AL: Type 2 diabetes mellitus among Florida children and adolescents, 1994-1998. Public Health Rep 117:373-379, 2002.
38. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B: Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161: 1125-1127, 2004.
39. McConville BJ, Sorter MT: Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65(Suppl 6):20-29, 2004.
40. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, for the Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
41. Mitka M: Alliance anxious about children's mental health. JAMA 284:31-32, 2000.
42. National Advisory Mental Health Council's Work-group on Child and Adolescent Mental Health Intervention Development and Deployment: Blueprint for change: Research on child and adolescent mental health (NIH Publication 01-4985). Rockville (Maryland), National Institute of Mental Health, 2001.
43. National Institute of Mental Health: CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:839-845, 1985.
44. Pandina G, Bilder R, Keefe R, Simpson G, Gharabawi G: Risperidone and cognitive function in children with disruptive behavior disorders. Scottsdale (Arizona), Janssen Pharmaceutica, CNS Advisory Summit, February 23-26, 2003 (poster).
45. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC II, Ketner S, Van Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D: "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121, 2002.
46. Pappadopulos E, MacIntyre JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive Youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003.
47. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML: Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996-2000. J Child Adolesc Psychopharmacol 12:221-229, 2002.
48. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M: Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 158: 266-269, 2001.
49. Raitasuo V, Vataja R, Elomaa E: Risperidone-induced neuroleptic malignant syndrome in a young patient. Lancet 344:1075, 1994.
50. Rohland BM, Rohrer JE, Culica D: Substitution of psychiatric care by primary care physicians: Impact of the Iowa Medicaid managed mental health care plan. Adm Policy Ment Health 26: 369-371, 1999.
51. Rosenheck RA: Organizational process: A missing link between research and practice. Psychiatr Serv 52:1598-1606, 2001.
52. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, MacIntyre JC II, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
53. Scolnick EM: CNS drug development in the 21st century. Boca Raton (Florida), National Institute of Mental Health, 43rd Annual New Clinical Drug Evaluation Unit Meeting, May 27-30, 2003 (presentation).
54. Sikich L: Comparative use of olanzapine and risperidone in psychotic youth. New Orleans (Louisiana), American Psychiatric Association, the 154th Annual Meeting, May 5-10, 2001 (symposium).
55. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, for the Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavioral disorders in children with sub-average IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
56. Taylor TK, Schmidt F, Pepler D, Hodgins C: A comparison of eclectic treatment with Webster-Stratton's Parent and Child Series in a children's mental health center: A randomized, controlled trial. Behav Ther 29:221-240, 1998.
57. Torrey WC, Drake RE, Dixon L, Burns BJ, Flynn L, Rush AJ, Clark RE, Klatzker D: Implementing evidence-based practices for persons with severe mental illnesses. Psychiatr Serv 52:45-50, 2001.
58. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
59. Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13, 2001.
60. Walkup JT, Labellarte MJ, Riddle MA, Pine D, Greenhill L, Klein R, Davies M, Sweeney M, Fu C, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J, O'Hara T, Baker S, Vitiello B, Ritz L, Roper M, for the Research Units on Pediatric Psychopharmacology Anxiety Study Group: Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:13-21, 2003.
61. Webster-Stratton C, Hammond M: Treating children with early-onset conduct problems: A comparison of child and parent training interventions. J Consult Clin Psychol 65:93-109, 1997.
62. Webster-Stratton C, Hammond M: Marital conflict management skills, parenting style, and early-onset conduct problems: Processes and pathways. J Child Psychol Psychiatry 40:917-927, 1999.
63. Webster-Stratton C, Herbert M: Strategies for helping parents of children with conduct disorders. Prog Behav Modif 29:121-142, 1994.
64. Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 57(Suppl 11):53-60, 1996.
65. Worrel JA, Marken PA, Beckman SE, Ruehter VL: Atypical antipsychotic agents: A critical review. Am J Health-Syst Pharm 57:238-258, 2000.
66. Young TK, Dean HJ, Flett B, Wood-Steiman P: Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr 136:365-369, 2000.
67. Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003.